Analyst Price Target is $4.00
▲ +189.86% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Context Therapeutics in the last 3 months. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 189.86% upside from the last price of $1.38.
Current Consensus is
Buy
The current consensus among 2 polled investment analysts is to buy stock in Context Therapeutics. This Buy consensus rating has held steady for over two years.
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Read More